What a peptide actually is

A peptide is a chain of amino acids — typically two to fifty residues — shorter than what biochemistry calls a protein but built from the same twenty letters. Your body is full of them. Insulin is a peptide. Oxytocin is a peptide. Growth-hormone-releasing hormone (GHRH) is a peptide. The word, on its own, tells you almost nothing about whether a molecule is safe, useful, or even regulated as a drug.

That is the first source of confusion in this space. "Peptide therapy" is a marketing category, not a pharmacological one. Inside it sit FDA-approved injectables with billions of dollars of phase-3 data, compounded gray-market compounds with promising animal work, and a long tail of speculative oligopeptides whose human evidence is thin and whose mechanism is mostly mechanism-on-paper.

The useful next question is always: which receptor, in which tissue, with what affinity, and what is the half-life? A GLP-1 (glucagon-like peptide-1) receptor agonist with a 168-hour half-life is a different animal from a five-amino-acid bioregulator with a serum half-life under ten minutes. They share the suffix and almost nothing else.

I will use the three-tier framework throughout: Established peptides have phase-3 data and at least one regulatory approval. Promising peptides have plausible mechanism and phase-1/2 or strong animal data, but the confirmatory human trial is either missing or underpowered. Speculative peptides have a mechanism story and community-reported effects, with little controlled human evidence either way.

The GLP-1 class — incretins, not anorectics

GLP-1 receptor agonists — semaglutide, liraglutide, tirzepatide, and the next-generation tri-agonists like retatrutide — are the most consequential peptide class to enter the consumer health conversation in a generation. They originated as type-2 diabetes drugs and earned their reputation in obesity trials. STEP-1 showed roughly 15 percent body-weight reduction at 68 weeks with weekly semaglutide [Wilding 2021]. SURMOUNT-1 pushed that to over 20 percent with tirzepatide [Jastreboff 2022].

The mechanism is not "appetite suppressant" in the old amphetamine sense. GLP-1 is an incretin: a gut-derived peptide that amplifies glucose-dependent insulin secretion, slows gastric emptying, and acts on hypothalamic and brainstem circuits that govern satiety [Drucker 2018]. The drugs are long-acting analogs of an endogenous signal. That is why the side-effect profile is dominated by gastrointestinal symptoms (the gut is where the receptor density is highest) and why the metabolic effects extend well past weight.

SELECT, the cardiovascular outcomes trial, showed a 20 percent reduction in major adverse cardiovascular events with semaglutide in adults with overweight or obesity and pre-existing cardiovascular disease [Lincoff 2023]. FLOW, the kidney trial, was stopped early for benefit [Perkovic 2024]. These are the kinds of trials that change clinical guidelines, and they are why I treat this class as established, not experimental.

The honest caveats: lean-mass loss tracks total-mass loss roughly one for three, which is why resistance training and adequate protein intake (1.2–1.6 g/kg) are not optional accessories [Phillips 2016]. Rebound after discontinuation is well-documented; in STEP-4, most of the weight returned within a year of stopping. And the compounded-semaglutide economy has its own quality-control questions that the on-label product does not.

GLP-1s are the first peptide class where the trial data and the consumer narrative actually line up. That is rarer than it sounds.

Growth-hormone peptides — the pulsatility argument

The growth-hormone peptide category — sermorelin, tesamorelin, CJC-1295, ipamorelin, GHRP-2, GHRP-6 — is built around a specific physiologic argument that I think is correct, and worth stating plainly.

Endogenous growth hormone (GH) is released in pulses, mostly during slow-wave sleep, under the control of GHRH (growth-hormone-releasing hormone) from the hypothalamus and ghrelin-receptor signaling from the stomach. The pituitary integrates these inputs and releases GH in bursts, which the liver converts (in part) to IGF-1 (insulin-like growth factor 1). Negative feedback from IGF-1 and somatostatin throttles the system. It is, by design, self-limiting.

Exogenous human growth hormone (HGH) bypasses all of that. It delivers a flat, supraphysiologic plateau of GH, suppresses endogenous production, and depending on dose, drives IGF-1 well above the age-adjusted reference range. The trade-off is the side-effect profile that long-running acromegaly literature has mapped in detail: insulin resistance, edema, carpal tunnel, and — in chronic supraphysiologic exposure — cancer-risk signals worth taking seriously [Bartke 2021].

GH-releasing peptides act upstream. A GHRH analog (sermorelin, tesamorelin, CJC-1295) plus a GH-secretagogue (ipamorelin, GHRP-2) prompts the pituitary to release the body's own GH in something approximating its natural pulse pattern, with negative feedback still intact. You get a GH signal without flooring the feedback loop. That is the pulsatility argument, and on the available human data — strongest for tesamorelin in HIV-associated lipodystrophy [Falutz 2007] — it holds up.

My editorial position, stated plainly: for age-related decline and recomposition goals in adults without a diagnosed deficiency, GH-releasing peptides are a better instrument than exogenous HGH. They preserve the pulse architecture, preserve the feedback, and cost a fraction of what injectable HGH does. They are not magic. They are not a substitute for sleep, protein, and load-bearing training. But the physiologic logic is cleaner, and the safety profile in the available trials is more forgiving.

Healing peptides — BPC-157 and TB-500

BPC-157 (body protection compound-157) is a fifteen-amino-acid fragment derived from a gastric protein. TB-500 is a synthetic analog of thymosin beta-4. The community case for both is built on a large body of rodent work showing accelerated tendon, ligament, gut-lining, and muscle healing across injury models [Sikiric 2018].

The rodent data are real and consistent. The controlled human data are thin. There is no phase-3 trial of BPC-157 in any orthopedic indication. Reported community use — typically subcutaneous injection at or near the injury site for two to four weeks — is widespread, and the anecdotal signal is strong enough that the absence of trials is itself worth noting. The reason there are no trials is partly economic (peptide fragments are hard to patent at the molecule level) and partly regulatory.

BPC-157 was added to the WADA prohibited list in 2022, which tells you athletes believe it works. It does not tell you it is safe at the doses and durations people use it. Long-term human safety data does not exist. Anyone telling you it definitely does not cause harm is making a claim the evidence cannot support. Anyone telling you it definitely does is also making a claim the evidence cannot support. The honest description is: promising mechanism, encouraging rodent data, unverified in humans.

PT-141 and sexual-function peptides

PT-141 (bremelanotide, marketed as Vyleesi) is a melanocortin-receptor agonist approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women [Kingsberg 2019]. It is one of the few peptides in this hub with full regulatory approval for a sexual-function indication.

Mechanism is central, not peripheral. Unlike PDE5 inhibitors (sildenafil, tadalafil) that act on vascular smooth muscle, PT-141 activates melanocortin-4 receptors in the central nervous system. That is why it works in both sexes, why nausea and transient blood-pressure elevation are the dominant side effects, and why it is dosed on-demand rather than chronically.

Outside the on-label use case, the compounded PT-141 market is sizable, and dosing in community use tends to be both higher and more frequent than the trial schedule. The drug works; that does not mean the community-use protocol is the right protocol. The trials used specific doses for a reason.

Bioregulators — the Khavinson controversy

Bioregulator peptides are very short sequences — two, three, or four amino acids — characterized largely by the work of Vladimir Khavinson and the Saint Petersburg Institute of Bioregulation and Gerontology over the past four decades. Epitalon (an alleged pineal-tissue tetrapeptide), thymalin (thymus), prostamax (prostate), and a long list of tissue-specific peptides come out of this lineage. The proposed mechanism is gene-expression modulation: small peptides binding promoter regions and shifting transcription in tissue-specific ways [Khavinson 2014].

Two things can be true at once. The Khavinson group has published a substantial volume of clinical work, much of it in Russian-language journals, reporting mortality and morbidity benefits in elderly cohorts over multi-decade follow-up. Western pharmacology has, with limited exceptions, not attempted to replicate the molecular-mechanism claims under modern controls. The result is a body of evidence that is internally extensive but externally under-validated — and the consumer marketplace has moved well past the evidence in either direction.

I treat bioregulators as the speculative tier. The mechanism is interesting. The trial infrastructure that would settle the question — pre-registered, controlled, externally replicated — does not yet exist outside the original research lineage. People using bioregulators are, in honest terms, betting on a model.

How to think about the class

Three rules, distilled from years of watching this category evolve.

First, the suffix is meaningless. "Peptide" tells you a molecule is short and amino-acid-based. It does not tell you anything about whether it works, whether it is safe, or whether the human trial exists. Always ask the next question: which receptor, what evidence tier, what dose, what half-life.

Second, mechanism is not effect. A drug that hits a receptor implicated in a process is a hypothesis, not a finding. The peptides with the strongest claims on your attention are the ones where the receptor story and the human outcome trial agree. That set is small.

Third, the compounded-pharmacy economy is doing more of this work than any other channel. That is both an access story (people get peptides their regulatory environment would not otherwise offer) and a quality-control story (the variability across compounders is real). Both things matter.